Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exelixis, Inc.

https://www.exelixis.com/

Latest From Exelixis, Inc.

Achieve Life Sciences Believes It Has The New Chantix

Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market. 

Clinical Trials Neurology

Fast Start To Oral Phenylephrine Efficacy Complaints As US FDA Considers 'Any Action'

Two days after FDA advisory panel’s meeting to discuss whether oral phenylephrine is effective for nasal congestion, complaints filed in federal court in multiple states alleging manufacturers knowingly misled public about ingredient’s efficacy. FDA’s potential response to NDAC’S finding wouldn’t come as soon.

Advisory Committees FDA

Exelixis Adds Insilico Deal In Search Of Growth Beyond Cabometyx

After feeling the heat from activist investor Farallon Capital Management earlier this year, CEO Michael Morrissey has defended its spending on in-house R&D and in-licensing as it announced a new oncology deal.

Commercial Companies

‘Small Biotech Exception’ From Medicare Price Negotiation Granted To Four Drugs For 2026

CMS has not disclosed how many requests for the exception it received but will follow up with applicants regarding its decisions this month.

Reimbursement Medicare
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • X-Ceptor Therapeutics, Inc.
UsernamePublicRestriction

Register